Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

361 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis.
Nader-Marta G, Monteforte M, Agostinetto E, Cinquini M, Martins-Branco D, Langouo M, Llombart-Cusac A, Cortés J, Ignatiadis M, Torri V, Apolone G, Cappelletti V, Pruneri G, de Azambuja E, Di Cosimo S. Nader-Marta G, et al. Among authors: torri v. ESMO Open. 2024 Mar;9(3):102390. doi: 10.1016/j.esmoop.2024.102390. Epub 2024 Mar 10. ESMO Open. 2024. PMID: 38460249 Free PMC article.
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies.
Nuccio A, Viscardi G, Salomone F, Servetto A, Venanzi FM, Riva ST, Oresti S, Ogliari FR, Viganò M, Bulotta A, Cameron R, Esposito A, Hines J, Bianco R, Reni M, Cascone T, Garassino MC, Torri V, Veronesi G, Cinquini M, Ferrara R. Nuccio A, et al. Among authors: torri v. Eur J Cancer. 2023 Dec;195:113404. doi: 10.1016/j.ejca.2023.113404. Epub 2023 Oct 26. Eur J Cancer. 2023. PMID: 37948842
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC.
Hines JB, Cameron RB, Esposito A, Kim L, Porcu L, Nuccio A, Viscardi G, Ferrara R, Veronesi G, Forde PM, Taube J, Vokes E, Bestvina CM, Dolezal JM, Sacco M, Monteforte M, Cascone T, Garassino MC, Torri V. Hines JB, et al. Among authors: torri v. J Thorac Oncol. 2024 Jul;19(7):1108-1116. doi: 10.1016/j.jtho.2024.03.010. Epub 2024 Mar 8. J Thorac Oncol. 2024. PMID: 38461929 Free article.
Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis.
Lacas B, Bourhis J, Overgaard J, Zhang Q, Grégoire V, Nankivell M, Zackrisson B, Szutkowski Z, Suwiński R, Poulsen M, O'Sullivan B, Corvò R, Laskar SG, Fallai C, Yamazaki H, Dobrowsky W, Cho KH, Beadle B, Langendijk JA, Viegas CMP, Hay J, Lotayef M, Parmar MKB, Aupérin A, van Herpen C, Maingon P, Trotti AM, Grau C, Pignon JP, Blanchard P; MARCH Collaborative Group. Lacas B, et al. Lancet Oncol. 2017 Sep;18(9):1221-1237. doi: 10.1016/S1470-2045(17)30458-8. Epub 2017 Jul 27. Lancet Oncol. 2017. PMID: 28757375 Free PMC article.
Adjuvant chemotherapy for resected early-stage non-small cell lung cancer.
Burdett S, Pignon JP, Tierney J, Tribodet H, Stewart L, Le Pechoux C, Aupérin A, Le Chevalier T, Stephens RJ, Arriagada R, Higgins JP, Johnson DH, Van Meerbeeck J, Parmar MK, Souhami RL, Bergman B, Douillard JY, Dunant A, Endo C, Girling D, Kato H, Keller SM, Kimura H, Knuuttila A, Kodama K, Komaki R, Kris MG, Lad T, Mineo T, Piantadosi S, Rosell R, Scagliotti G, Seymour LK, Shepherd FA, Sylvester R, Tada H, Tanaka F, Torri V, Waller D, Liang Y; Non‐Small Cell Lung Cancer Collaborative Group. Burdett S, et al. Among authors: torri v. Cochrane Database Syst Rev. 2015 Mar 2;2015(3):CD011430. doi: 10.1002/14651858.CD011430. Cochrane Database Syst Rev. 2015. PMID: 25730344 Free PMC article. Review.
Corrigendum to "Moderate physical activity during neoadjuvant chemotherapy in breast cancer patients: effect on cancer-related inflammation and pathological complete response-the Neo-Runner study": [ESMO Open 9 (2024) 10.1016/j.esmoop.2024.103665].
Garrone O, Paccagnella M, Abbona A, Ruatta F, Vanella P, Denaro N, Tomasello G, Croce N, Barbin F, Rossino MG, La Porta CAM, Sapino A, Torri V, Albini A, Merlano MC. Garrone O, et al. Among authors: torri v. ESMO Open. 2024 Nov;9(11):103983. doi: 10.1016/j.esmoop.2024.103983. Epub 2024 Oct 28. ESMO Open. 2024. PMID: 39617533 Free PMC article. No abstract available.
Moderate physical activity during neoadjuvant chemotherapy in breast cancer patients: effect on cancer-related inflammation and pathological complete response-the Neo-Runner study.
Garrone O, Paccagnella M, Abbona A, Ruatta F, Vanella P, Denaro N, Tomasello G, Croce N, Barbin F, Rossino MG, La Porta CAM, Sapino A, Torri V, Albini A, Merlano MC. Garrone O, et al. Among authors: torri v. ESMO Open. 2024 Aug;9(8):103665. doi: 10.1016/j.esmoop.2024.103665. Epub 2024 Aug 8. ESMO Open. 2024. PMID: 39121813 Free PMC article.
A Response Letter by Cameron et al.
Cameron RB, Hines JB, Torri V, Garassino MC. Cameron RB, et al. Among authors: torri v. J Thorac Oncol. 2024 Aug;19(8):e26-e28. doi: 10.1016/j.jtho.2024.05.365. J Thorac Oncol. 2024. PMID: 39112011 No abstract available.
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial.
Colombo N, Biagioli E, Harano K, Galli F, Hudson E, Antill Y, Choi CH, Rabaglio M, Marmé F, Marth C, Parma G, Fariñas-Madrid L, Nishio S, Allan K, Lee YC, Piovano E, Pardo B, Nakagawa S, McQueen J, Zamagni C, Manso L, Takehara K, Tasca G, Ferrero A, Tognon G, Lissoni AA, Petrella M, Laudani ME, Rulli E, Uggeri S, Barretina Ginesta MP; AtTEnd study group. Colombo N, et al. Lancet Oncol. 2024 Sep;25(9):1135-1146. doi: 10.1016/S1470-2045(24)00334-6. Epub 2024 Aug 2. Lancet Oncol. 2024. PMID: 39102832 Clinical Trial.
361 results